Global Market Intelligence Service

We proudly deliver best-in-class consulting services to our clients in the Life Sciences Industry. Our team is built based on high levels of industry expertise and a strong commitment to serving as a strategic partner to our clients. We believe teamwork and trust provide a foundation for optimal results. As Excellis continues to achieve success, we encourage our employees to take leadership initiative within the company.

GMIS_Logo-091515

Excellis Health Solutions offers a service to ensure the most up-to-date information pertaining to legislation and how it may affect your company through a yearly subscription.
Global Track and Trace (GTT) members can access GMIS country slide information through the link below.

Click Here

GMIS – Recent News

FDA Guidance for DSCSA
On September 19, 2018, the USFDA published a Draft Guidance, Product Identifiers Under the Drug Supply Chain Security Act – Questions and Answers, [Docket Number FDA-2018-D-3175-0002]. This draft guidance introduced some recommendations that were, at the very least, confusing if not confounding to the pharmaceutical supply chain’s strategy, systems, and validated processes that have been widely adapted for compliance to the DSCSA regulation.
Continue Reading


DSCSA T3 Data Standardization & Documentation Practices
The FDA released the draft guidance which provides a significant amount of detail regarding the standardization of product tracing information, its specific data elements; and recommended documentation practices trading partners may utilize to satisfy their product tracing requirements. This guidance supplements the DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs: How to Exchange Product Tracing Information guidance released in November 2014.
Continue Reading


FDA Key Definitions for Suspect & Illegitimate Product Verification

The FDA released its draft guidance which provides FDA’s interpretation of the terms counterfeit, diverted, fraudulent transaction, and unfit for distribution to aid trading partners in their determination of whether a given product is suspect and/or illegitimate.
Continue Reading


European Medicines Verification Organization (EMVO) Published Onboarding Deadlines
With the deadline for the Falsified Medicines Directive (FMD) approaching, EMVO has issued guidance as it relates to the On-boarding process for manufacturers. This guidance advises all On-Boarding Partners and future On-Boarding Partners that the final opportunity to on-board into EMVO with a guarantee of making compliance deadlines is June 2018.
Continue Reading


European Medicines Verification Organization (EMVO) Published Onboarding Deadlines
With the deadline for the Falsified Medicines Directive (FMD) approaching, EMVO has issued guidance as it relates to the On-boarding process for manufacturers. This guidance advises all On-Boarding Partners and future On-Boarding Partners that the final opportunity to on-board into EMVO with a guarantee of making compliance deadlines is June 2018.
Continue Reading


“USFDA Publishes Guidance of Enforcement Discretion for UDI (Unique Device Identification) Compliance Dates – Class I and Unclassified Devices”
On January 16, 2018, the FDA released a guidance document, Unique Device Identification: Policy Regarding Compliance Dates for Class I and Unclassified Devices. This guidance, with initial intent released in June 2017, describes FDA’s intention with regard to enforcement of these requirements for class I and unclassified devices.
Continue Reading


The Russian Federation Closes in on a Serialized Track and Trace Model
On January 24, 2017, the Government of the Russian Federation and several government agencies announced and released a decree to implement a system for the identification and monitoring of all pharmaceutical products in the Russian market, known as the “Medicines Quality and Safety” project.
Continue Reading


The FDA Has Spoken: Grandfathering Guidance Has Been Released!
The FDA released the Grandfathering policy on November 27, 2017. Although this guidance is exactly two years late (Based on the DSCSA timeline), it provides clear direction on the grandfathering policy.
Continue Reading

Excellis is excited to announce that we are an official GS1 Solution Partner!

2016 GS1 US Solution Partner Trustmark Debra.jpg

Not a Member? Register for GMIS Today!